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Abstract
IL-33 is an IL-1-related cytokine that can act as an alarmin when released from
necrotic cells. Once released, it can target various immune cells including mast
cells, innate lymphoid cells and T cells to elicit a Th2-like immune response.
We show here that bone marrow-derived mast cells produce IL-13, IL-6, TNF,
GM-CSF, CCL3 and CCL4 in response to IL-33 stimulation. Inhibition of the
p38 MAPK, or inhibition or knockout of its downstream kinases MK2 and
MK3, blocked the production of these cytokines in response to IL-33. The
mechanism downstream of MK2/3 was cytokine specific; however, MK2 and
MK3 were able to regulate TNF and GM-CSF mRNA stability. Previous studies
in macrophages have shown that MK2 regulates mRNA stability via
phosphorylation of the RNA-binding protein TTP (Zfp36). The regulation of
cytokine production in mast cells was, however, independent of TTP. MK2/3
were able to phosphorylate the TTP-related protein Brf1 (Zfp36 l1) in IL-33-
stimulated mast cells, suggesting a mechanism by which MK2/3 might control
mRNA stability in these cells. In line with its ability to regulate in vitro IL-33-
stimulated cytokine production, double knockout of MK2 and 3 in mice
prevented neutrophil recruitment following intraperitoneal injection of IL-33.
INTRODUCTION
IL-33 is an IL-1-related cytokine that was identified
through screening for ligands for the IL-1 receptor
family member ST2,1 and it is now established as the
major in vivo ligand for the ST2 receptor.2-4
Constitutive IL-33 expression has been observed in non-
hematopoietic cells, primarily epithelial and endothelial
cells. While IL-1b and IL-18 require cleavage by the
inflammasome in order for their secretion and biological
activity, this is not true for IL-33. IL-33 lacks a
conventional signal peptide and caspase cleavage of IL-
33 results in its inactivation.5,6 This led to the proposal
that IL-33 acts as an alarmin following its release from
necrotic cells.7
The IL-33 receptor comprises the ST2 (Il1rl1) chain in
combination with the IL-1RAcP protein.8 ST2 expression
and IL-33 responsiveness have been reported in a number
of cells, notably mast cells,9 type 2 innate lymphoid
cells10-12 and some Th subsets including Tregs and Th2
cells.13-15 Like other members of the IL-1/TLR receptor
superfamily, following ligand binding, the ST2/IL-1RacP
dimer is able to recruit the signaling adaptor Myd88.16,17
Recruitment of Myd88 promotes the formation of a
Myd88osome that includes IRAK4 as well as IRAK1 and/
or IRAK2 that is able to activate Traf6.18 In agreement
with this, IL-33 requires Traf6 to activate both the MAPK
and NF-jB pathways,19 which in turn promote the
production of proinflammatory mediators.17,20,21 For
example, IL-33-stimulated mast cells have been shown to
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secrete IL-6, IL-13, TNF, MCP-1 and prostaglandin
D2.16,22-24 In contrast to IgE receptor-mediated mast cell
activation, IL-33 stimulation alone does not promote
mast cell degranulation.1,16
The p38 MAPK family consists of four isoforms and
acts downstream of cellular stress and inflammatory
signals. A role for p38 in the regulation of cytokine
production was initially suggested by the finding that a
class of pyridinyl imidazoles typified by SB203580,
reduced TNF production via inhibition of p38. This led
to the development of a large number of p38 inhibitors,
most of which target the p38a and b isoforms, although
work with gene targeted mice has shown that in
macrophages p38a, and not b, is the critical isoform for
the regulation of TLR-induced proinflammatory cytokine
production.18 p38a is able to activate further downstream
kinases, including MKs and MSKs, which can contribute
to the ability of p38 to regulate cytokine production.18
While MK2 and MK3 are solely activated by p38 in vivo,
MSK1 and the related kinase MSK2 are direct substrates
for both p38a and ERK1/2.18 Work in macrophages has
shown that MSKs induce anti-inflammatory feedback
pathways and are required for the production of IL-10 by
these cells.25,26 Knockout of MK2 was found to reduce
TNF production in response to TLR agonists both in vivo
and in isolated macrophages.27 While MK2 appears to be
the more dominant isoform, some compensation does
exist between MK2 and MK3, as double knockout of
both MK2 and MK3 resulted in a greater suppression of
TNF production than knockout of MK2 alone following
intraperitoneal injection of LPS in mice.28 In
macrophages, the major mechanism by which MK2 and
MK3 regulate the production of TNF is via
phosphorylation of the mRNA-binding protein TTP (also
known as Zfp36).29,30 TTP is an mRNA-binding protein
that recognizes AU-rich elements in the 30UTR of certain
mRNAs including that of TNF.31 Once bound, TTP can
both inhibit the translation of the mRNA and promote
its degradation. TTP is phosphorylated by MK2 on at
least two sites and this inhibits the ability of TTP to
repress translation or promote RNA degradation.30,32,33 A
critical role for TTP in repressing TNF production has
been shown both in vivo and in isolated macrophages
using TTP knockout mice.34,35 Surprisingly, bone
marrow-derived mast cells from TTP knockout mice
showed normal production of TNF and IL-6 in response
to LPS.21 This was attributed to a low basal expression of
TTP in mast cells as judged by immunoblotting.21
Despite this, TTP may still play a role in mast cells under
some circumstances; mast cells upregulate TTP mRNA in
response to IL-4 stimulation and this has been proposed
to explain the repression of IgE-induced TNF production
by IL-4.36 Recently, MK2 and MK3 have been suggested
to play a role in IL-6 and IL-13 induction in IL-33-
stimulated mast cells and IL-13 in dendritic cells;
however, the substrate targeted by MK2 in these cells is
not clear.24,37 We show here that knockout or inhibition
of MK2 and MK3 in mast cells blocks TNF, IL-6, IL-13,
GM-CSF, CCL3 and CCL4 production in response to IL-
33, and that this occurs via both transcriptional and
post-transcriptional mechanisms. We also show that
the TTP-related protein Brf1 is expressed in mast cells
and is phosphorylated by MK2/3 in these cells following
IL-33 stimulation.
RESULTS
IL-33 induced cytokine production in BMMCs requires
p38 MAPK
The IL-33 receptor is part of IL-1 receptor/TLR family of
receptor family and acts via Myd88 to stimulate MAPK
and NF-jB activation. Consistent with previous
reports,38-40 IL-33 was found to activate p38a in bone
marrow-derived mast cells (BMMCs), as judged by
phosphorylation of its TXY activation motif. The
activation of p38a was absent in BMMCs from Myd88
knockout mice (Supplementary figure 1). To examine the
roles of p38a in IL-33-induced cytokine induction,
BMMCs were treated with the p38a/b inhibitor VX-745
prior to stimulation with IL-33. Pretreatment with VX-
745 did not affect the phosphorylation of p38a on its
TXY motif, which is catalyzed by the upstream kinases
MKK3 and -6, but did block the phosphorylation of the
p38a substrate MK2 (Figure 1a). IL-33 also induced the
activation of MSK1, as judged by its phosphorylation on
Ser376, a site that correlates to MSK1 activation,41 as well
as the phosphorylation of the MSK substrate CREB. VX-
745 did not prevent MSK1 or CREB phosphorylation,
suggesting that as in other cell types, IL-33 activates
MSKs in part via the ERK1/2 pathway. To examine the
role of p38a in cytokine induction in BMMCs, cells were
stimulated for 8 h with IL-33 and the secretion of TNF,
IL-6, IL-13 and GM-CSF, as well as the chemokines
CCL3 and CCL4, was analyzed. IL-33 was able to
stimulate the production of the cytokines and
chemokines tested, and in each case, pretreatment with
VX-745 was able to inhibit their production (Figure 1b).
IL-33-induced cytokine production requires the p38-
activated kinases MK2 and MK3
As p38a can mediate its effects via downstream kinases,
the role of MSK1/2 or MK2/3 knockout in IL-33-induced
cytokine induction was examined. Bone marrow from
MSK1/2 double knockout mice was able to differentiate
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into BMMCs, as judged by similar expression of c-kit and
FceRI and ST2 to wild-type BMMCs (Supplementary
figure 2). IL-33 induced phosphorylation of MSK1 and
its substrates CREB and ATF1 (Supplementary figure 3a,
b). In line with the ability of both p38 and ERK1/2 to
activate MSK1, inhibition of both pathways was required
to fully block MSK1 and CREB phosphorylation
(Supplementary figure 3a). As expected, IL-33-stimulated
phosphorylation of CREB was lost in MSK1/2 knockout
cells (Supplementary figure 3b). MSK1/2 knockout cells
produced similar levels of TNF, IL-6, IL-13 and GM-CSF
to wild-type cells in response to IL-33 stimulation
(Supplementary figure 3c). In line with the levels of
secreted cytokines, the induction of TNF, IL-6, IL-13 and
GM-CSF mRNA was similar in wild-type and MSK1/2
knockout BMMCs. Although MSK1/2 knockout did not
have a major impact on IL-33-induced cytokine
induction, it did greatly reduce the induction of nur77
mRNA (Supplementary figure 3d), an immediate early
gene previously shown to be both MSK and CREB
dependent in fibroblasts.42,43
MK2/3 knockout did not affect the differentiation of
BMMCs, and both wild-type and MK2/3 knockout
BMMCs expressed similar levels ST2 (Supplementary
figure 2). Knockout of MK2/3 in BMMCs resulted in a
decreased expression of p38a (Figure 2a). This decreased
level of p38a is due to a kinase activity-independent role
for MK2 in stabilizing p38 prior to activation, and is
consistent with what has been reported in other cell types
in MK2 single or MK2/3 double knockouts.27,44,45 Despite
this, p38a activation, as judged by its phosphorylation,
following IL-33 stimulation was still apparent, albeit at a
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Figure 1. p38 is required for cytokine secretion in IL-33-stimulated BMMCs. (a) BMMCs were isolated from wild-type mice. Where indicated,
cells were pretreated for 1 h with 1 lM VX-745 before stimulation with 10 ng mL1 IL-33 for the indicated times. The levels of the indicated
proteins were then determined by immunoblotting. (b) As in a, but BMMCs were stimulated with 10 ng mL1 IL-33 for 8 h and the levels of
TNF, IL-6, IL-13, GM-CSF, CCL3 and CCL4 determined as described in the methods. Graphs represent the mean and standard deviation of results
from independent cultures from four mice. For a comparison with the IL-33-stimulated condition, a P-value (two-tailed Student’s t-test) of <0.05
is indicated by *, <0.01 by ** and <0.001 by ***. BMMC, bone marrow-derived mast cells.
3
PC McCarthy et al. MK2/3 regulate IL-33-induced mast cell responses
lower level than in wild-type cells (Figure 2a). MK2/3
knockout BMMCs produced greatly reduced levels of
TNF, IL-6, IL-13, GM-CSF, CCL4 and CCL4 following
IL-33 stimulation relative to wild-type cells (Figure 2b).
While these data are consistent with a role for MK2 and
MK3 in directly regulating cytokine production in
BMMCs, the results in the knockout could also be
explained by an indirect mechanism because of the
decreased levels of p38a in the MK2/3 knockout cells. To
resolve this, three different MK2/3 inhibitors were used,
PF-3644022, Cmp28 and Cmp2s. MK2 and MK3 are
known to phosphorylate Hsp27.46 As Hsp27 is not
detectable in BMMCs, Cmp28 and Cmp2s were titrated
in HeLa cells to determine the concentration required to
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Figure 2. Regulation of IL-33-induced cytokine production by MK2/3. (a) Wild-type or MK2/3 knockout BMMCs were stimulated for the
indicated times with 10 ng mL1 IL-33 and the levels of total and phospho-p38, total and phospho-MK2 determined by immunoblotting. Total
ERK1/2 was examined as a loading control. (b) BMMCs from wild-type or MK2/3 knockout mice were stimulated with 10 ng mL1 IL-33 for 0, 4,
8 or 16 h, and the levels of TNF, IL-6, IL-13, GM-CSF, CCL3 and CCL4 secreted into the media were determined. Graphs represent the mean and
standard deviation of results from independent cultures from four wild-type mice or three MK2/3 knockout mice. Two-way ANOVA indicated a
significant effect of genotype on all the cytokines tested, (P < 0.001, F = 233, 135, 102, 424, 334 or 514 for TNF, IL-6, IL-13, GM-CSF, CCL3 or
CCL4, respectively). For individual time points, P-value (post hoc Holm–Sidak testing) of <0.05 is indicated by *, <0.01 by ** and <0.001 by ***.
N.D. indicates a condition for which values not determined. (c) Wild-type BMMCs were pretreated with 5 lM PF-3644022, 5 lM Cmp28 or 5 lM
Cmp2s for 1 h where indicated and then stimulated with 10 ng mL1 IL-33 for the indicated times. The levels of the indicated proteins were
determined by immunoblotting. (d) BMMCs were pretreated with 5 lM PF-3644022, 5 lM Cmp28 or 5 lM Cmp2s for 1 h as shown and then
either left unstimulated or stimulated with 10 ng mL1 IL-33 for 8 h. The levels of TNF, IL-6, IL-13 and GM-CSF secreted into the media were
determined as described in the methods. Graphs represent the mean and standard deviation of results from four independent stimulations. For a
comparison with the no inhibitor, IL-33 stimulated condition, a P-value (post hoc Holm–Sidak test after one-way ANOVA) of <0.001 is indicated
by ***. BMMC, bone marrow-derived mast cells.
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block Hsp27 phosphorylation in response to anisomycin,
a strong activator of the p38–MK2 pathway.47 This
showed that 5 lM of either compound was able to inhibit
MK2/3 in cells (Supplementary figure 4). Previous studies
have shown that 5 lM of PF-3644022 is able to block
Hsp27 phosphorylation in HeLa cells.48 To examine
potential off-target activities of Cmp28 and Cmp2s, the
compounds were screened in vitro against a panel of 290
kinases. At 1 lM, both these compounds inhibited MK2
and MK3 by more than 90%. Cmp2s inhibited PRAK by
72%, but none of the other kinases were inhibited by
more than 50%. Cmp28 did not inhibit any of the other
kinases tested by more than 25% (Supplementary figure
4, table 1). The screening of PF-3644022 showed that it
was more potent against MK2 than MK3, and that it
showed more off-target activities than Cmp2s and Cmp28
(Supplementary figure 4, table 1).
As the stabilization of p38a by MK2 is independent of
the kinase activity of MK2,45 inhibitors of MK2 and MK3
would not be expected to affect p38a expression or
activation. Consistent with this, treatment of BMMCs
with PF-3644022, Cmp28 or Cmp2s did not affect p38
levels or activation in response to IL-33 in BMMCs
(Figure 2c). Pretreatment of BMMCs with PF-3644022,
Cmp2s or Cmp28 for 1 h before stimulation with IL-33
inhibited the production of TNF, IL-6, IL-13 and GM-
CSF (Figure 2d). Together, these results are consistent
with MK2 and MK3 directly regulating cytokine
induction downstream of p38a in IL-33-stimulated mast
cells. Similar to that observed in BMMCs, cultured
peritoneal mast cells also secreted TNF, IL-6, IL-13 and
GM-CSF in response to IL-33, and this was blocked by
the MK2 inhibitor Cmp2s (Supplementary figure 5).
The role of MK2 and MK3 has previously been
examined in TLR signaling which, similar to IL-33, can
act via Myd88-dependent signaling. This work has focused
predominantly in macrophages and dendritic cells where
MK2 is required for maximal TNF production.28 It is less
clear if loss of MK2 and MK3 results in a general block in
cytokine induction in these cells as was seen in BMMCs
(Figure 2). To determine whether this was due to a
difference between IL-33 and TLR agonists or a mast cell-
specific effect, cytokine induction in LPS-stimulated MK2/
3 knockout mast cells and bone marrow-derived
macrophages (BMDMs) was examined. LPS was used, as
IL-33 did not induce cytokine production in BMDMs
(data not shown). BMDMs produced TNF, IL-6, IL-12p70
and IL-12p40 in response to LPS. MK2/3 knockout
BMDMs produced lower amounts of TNF than wild-type
cells in response to LPS; however, IL-6, IL-12p70 and IL-
12p40 production was not reduced (Supplementary figure
6a). BMDMs were obtained via culture of bone marrow
cells in M-CSF. Differentiation of bone marrow cells with
GM-CSF gives rise to a heterogeneous macrophage/
dendritic cell population.49 LPS-induced TNF secretion
was decreased in MK2/3 knockout cells relative to wild-
type cells in GM-CSF differentiated cultures while only
minor effects were seen on IL-6, IL-13 and IL-12p40
secretion (Supplementary figure 6b). To examine the role
of MK2/3 in cytokine production in TLR-stimulated mast
cells, BMMCs were stimulated with TLR4 agonist LPS.
Similar to IL-33, LPS was able to stimulate TNF, IL-6, IL-
13 and GM-CSF production in BMMCs, and in each case,
the production of these cytokines was reduced by MK2/3
knockout (Supplementary figure 6c). In line with this,
LPS-induced cytokine production in BMMCs was
inhibited by the MK2/3 inhibitors PF-3604422 and Cmp2s
(Supplementary figure 7).
In macrophages, MK2 regulates TNF production via the
phosphorylation of TTP, a protein that binds to AU-rich
elements in the 30UTR of a subset on mRNAs resulting in
destabilization of the mRNA.31,50 To determine whether
MK2/3-mediated TTP phosphorylation could explain the
effects of MK2/3 knockout in mast cells, BMMCs were
derived from TTP knockout bone marrow. Loss of TTP
did not have a major effect on the IL-33 induced secretion
of TNF, IL-6, IL-13 or GM-CSF (Figure 3a). To confirm
these findings, BMMCs were also generated from mice
carrying alanine mutations at the two major MK2
phosphorylation sites, Ser52 and Ser178, in TTP.30 Again,
the IL-33 induced secretion of TNF, IL-6, IL-13 and GM-
CSF was similar in TTP knockin and wild-type BMMCs.
Furthermore, pretreatment of the knockin cells with either
PF-3604422, Cmp2s or Cmp28 was able to inhibit
cytokine induction, indicating that MK2 and MK3 could
act independently of TTP phosphorylation (Figure 3b).
The p38–MK2/3 pathway regulates IL-33 induced
translation of TNF
To examine the mechanism by which MK2/3 regulates IL-
33-induced cytokine production, the effects of MK2/3
knockout on cytokine mRNA induction was examined.
IL-33 stimulation increased the mRNA levels for TNF, IL-
6, GM-CSF and IL-13 in wild-type BMMCs. Loss of MK2
and MK3 did not greatly affect the induction of either
TNF mRNA or the unspliced primary TNF transcripts
relative to wild-type cells (Figure 4a, b). To examine the
upregulation of TNF protein, cells were stimulated with
IL-33 in the presence of agents that block secretion and
then intracellular levels of TNF determined by flow
cytometry. This showed that, unlike wild-type cells, MK2/
3 knockout BMMC failed to upregulate TNF protein in
response to IL-33 (Figure 4c). Similar effects on TNF
protein induction were seen by pretreating wild-type cells
with the MK2 inhibitor PF-3644022 (Figure 4d). MK2/3
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knockout BMMCs showed reduced mRNA induction of
IL-6 and IL-13 in response to IL-33 relative to wild-type
cells, with the maximal effect seen around 1 h of
stimulation. This correlated to a lower induction of the
primary transcript for IL-13, and to a lesser extent IL-6, in
MK2/3 knockout cells at this time point (Figure 4a, b).
For GM-CSF, the initial induction of mRNA was normal
in the MK2/3 knockouts; however, levels were lower in
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standard deviation of independent cultures from four mice per genotype. A P-value (Holm–Sidak test following two-way ANOVA testing)
between wild type and knockout of <0.05 is indicated * and P < 0.001 by ***. A P-value for the comparison of inhibitor treated conditions and
the IL-33-stimulated sample within one genotype of <0.001 is shown by +++.
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Figure 4. Effect of MK2/3 knockout in BMMCs on IL-33-induced cytokine mRNA levels. (a) BMMCs from wild-type or MK2/3 knockout mice
were stimulated with 10 ng mL1 IL-33 for the indicated times. Cells were then lysed, total RNA was isolated and cytokine induction was
determined by qPCR as described in the methods. The induction of TNF, IL-6, IL-13 and GM-CSF mRNA relative to wild-type unstimulated cells is
shown. Two-way ANOVA indicated a significant effect of genotype on IL-6 (F = 55.12, P < 0.001), IL-13 (F = 23.27, P < 0.001) and GM-CSF
(F = 6.23, P = 0.019). (b) As in a, but primary unspliced transcript (1o transcript) levels in the same cDNA samples were determined. In a and b,
graphs represent the mean and standard deviation of results from independent cultures from four wild-type mice or three MK2/3 knockout mice.
Two-way ANOVA indicated a significant effect of genotype on IL-6 (F = 6.92, P = 0.014). In (a) and (b) for comparisons between genotype at
individual time points, a P-value (post hoc Holm–Sidak test following two-way ANOVA) of <0.05 is indicated by *, <0.01 by ** and <0.001 by
***. (c) Wild-type or MK2/3 knockout BMMCs were stimulated for 4 h with 10 ng mL1 in the presence of 3 lg mL1 Brefeldin A and 2 lM
Monensin to block cytokine secretion. Cells were then fixed and permeabilized, stained for TNF and analyzed by flow cytometry. (d) As in c,
except wild-type cells were pretreated with 5 lM PF-3644022 for 1 h where indicated. In c and d, data are representative of two biological
replicates.
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MK2/3 knockouts compared to wild-type BMMCs at 8 h
of LPS stimulation (Figure 4a).
To determine whether MK2/3 knockout might affect
cytokine RNA stability, cells were stimulated for 1 h with
IL-33 and further transcription blocked by the addition
of DRB (5,6-dichloro-1b-1-ribofuranosylbenzimidazole)
and actinomycin D and the decay of mRNA levels
measured over time. TNF mRNA was unstable and
decayed with a half-life of approximately 55 min in wild-
type cells (Figure 5a). In MK2/3 knockout BMMCs, TNF
mRNA was less stable with a half-life of approximately
30 min. In wild-type cells, IL-6, IL-13 and GM-CSF
mRNAs were found to be stable (half-life >2 h).
Knockout of MK2/3 did not have a major effect on the
stability of IL-6 or IL-13 mRNA; however, MK2/3
knockout did decrease the stability of the GM-CSF
mRNA (Figure 5a). Similar results were observed when
cells were stimulated for 3 h with IL-33 before the
addition of DRB and actinomycin D (data not shown).
MK2/3 phosphorylate Brf1 in response to IL-33
While the effects of MK2/3 on TNF and GM-CSF
production BMMCs are TTP independent, MK2 has been
reported to phosphorylate Brf1, a TTP-related protein,
in vitro and in the fibrosarcoma cell line, HT1080.51 Brf1
protein levels were increased in IL-33 stimulated BMMCs
(Figure 5a), as were mRNA levels for both Brf1 and Brf2
(Supplementary figure 8). Multiple bands were observed
in the immunoblots, consistent with the multiple
phosphorylation sites known to occur on Brf1 affecting
its electrophoretic mobility on SDS-polyacrylamide gels.
Knockout of MK2 and MK3 resulted in a decreased
phosphorylation of Brf1 as judged by the decrease in the
upper band in the Brf1 blots from MK2/3 knockout
compared to wild-type BMMCs. Similar results were
observed when cells were treated with the MK2/3
inhibitor cmp2s (Figure 5c). Brf1 has been reported to be
phosphorylated on several sites including Ser92. Blotting
with a phospho-specific antibody for this site showed that
MK2/3 knockout or MK2/3 inhibitor reduced the IL-33
induced phosphorylation of Brf1 on this site in mast cells
(Figure 5b, c). Phosphorylation of Brf1 has been reported
to enable it to interact with 14-3-3 proteins.52,53 In line
with this, more Brf1 was observed in 14-3-3 pulldowns
from lysates from IL-33-stimulated BMMCs relative to
unstimulated cells. This was blocked by knockout of
MK2/3 (Figure 5d) or pretreatment of wild-type cells
with an MK2/3 inhibitor (Figure 5e). To confirm that the
Brf1 in the 14-3-3 pulldowns was phosphorylated, 14-3-3
pulldowns were treated with k phosphatase and then
analyzed by immunoblotting. This showed that the Brf1
in the phosphatase-treated samples ran at a lower
molecular weight, as would be expected with the removal
of phosphate groups (Supplementary figure 9). Blotting
of the pulldowns with an antibody that recognizes the
phosphorylation of Brf1 on Ser92 also indicated that Brf1
was phosphorylated in the pulldowns and that this
phosphorylation can be removed by the phosphatase
treatment (Supplementary figure 9).
PI3K signaling is required for maximal IL-33-induced
cytokine production
In addition to being phosphorylated by MK2 and/or 3,
Brf1 has also been reported as a substrate for Akt.52,53 A
role for MK2 and 3 in the activation of Akt has previously
been found in TLR-stimulated macrophages.48 To
determine whether Akt might play a role in regulating IL-
33-induced cytokine production, the Akt inhibitors Akti
1/2 and MK-2206 as well as the PI3 kinase inhibitors
GDC-0941 and PI-103 were used. All four inhibitors
reduced the induction of TNF, IL-6, IL-13 and GM-CSF
(Figure 6a). Analysis of cytokine mRNA induction
showed that inhibition of PI3 kinase or Akt reduced the
induction of TNF and IL-13 mRNA in response to IL-33
(Figure 6b). GM-CSF mRNA was not significantly
affected (P > 0.05) by PI3 kinase inhibitors, although
some reduction was seen in the presence of Akt inhibitors.
IL-6 mRNA levels were not affected by either PI3 kinase
or Akt inhibitors following 1 h of IL-33 stimulation
(Figure 6b). While both MK2/3 and Akt are involved in
IL-33-induced cytokine induction, the smaller inhibition
seen by blocking PI3 kinase compared to MK2/3 indicate
that the effects of MK2/3 knockout cannot be fully
explained by cross talk between the MK2/3 and Akt
pathways. To confirm this, MK2/3 inhibitors were added
in combination with a PI3 kinase inhibitor. As in
Figure 6a, GDC-0941 and PI-103 reduced IL-33-induced
TNF, IL-6, IL-13 and GM-CSF production. The remaining
cytokine production in the presence of PI3 kinase
inhibitors could however be further reduced by the
addition of the MK2 inhibitor PF-3604422 (Figure 6c).
Finally, we tested if the phosphorylation of Akt on Thr308
and Ser473 required MK2/3 in IL-33-stimulated BMMCs.
Both residues were phosphorylated in response to IL-33 in
wild-type cells. In MK2/3 knockout cells, the
phosphorylation of Akt on both Thr308 and Ser473 was
reduced following 30 min of stimulation; however, at
60 min after IL-33 stimulation, Akt phosphorylation on
Ser473 was slightly enhanced in the MK2/3 knockout
relative to wild-type cells (Figure 6d). Similar effects were
observed with the p38 inhibitor VX-745 (Figure 6e). This
would indicate that p38–MK2/3 signaling regulates the
kinetics of Akt activation, but is not completely essential
for IL-33-induced Akt activation.
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Figure 5. Effect of MK2/3 knockout on cytokine mRNA stability in IL-33-stimulated BMMCs. (a) Wild-type or MK2/3 knockout BMMCs were
stimulated with 10 ng mL1 IL-33 for 1 h. A quantity of 5 lg mL1 actinomycin D and 50 lM DRB were then added to block transcription. Total
RNA was isolated at 0, 0.5, 1 and 2 h after addition of actinomycin D and DRB and the levels of TNF, IL-6, IL-13 and GM-CSF mRNA determined
by qPCR. Graphs show the mean and standard deviation of independent cultures from four mice per genotype. Two-way ANOVA showed a
significant effect of genotype for TNF and GM-CSF (F = 112.255, P < 0.001 and F = 51.582 P < 0.001, respectively). For individual time points,
in post hoc testing P-values between wild type and knockout of <0.05 are indicated * and <0.001 by ***. (b) Wild-type or MK2/3 KO BMMCs
were stimulated with 10 ng mL1 IL-33 for the indicated times. Cells were then lysed and the levels phosho-Ser92 Brf1, Brf1, p-p38, total p38
and GAPDH were determined by immunoblotting. (c) Wild-type BMMCs were incubated where indicated with 5 lM VX-745 or 5 lM Cmp28.
Cells were stimulated with 10 ng mL1 IL-33 for the times shown and blotted for the indicated proteins. (d) Wild-type or MK2/3 knockout
BMMCs were stimulated with 10 ng mL1 IL-33 for the indicated times. Cells were then lysed and 14-3-3 pulldowns performed as described in
the methods. Pulldowns were blotted for the presence of Brf1 while lysates were blotted for phospho p38, total p38 and GAPDH. (e) Wild-type
BMMCs where incubated for 1 h with DMSO or 5 lM Cmp2s before stimulation with 10 ng mL1 IL-33 for the indicated times. Cells were then
lysed and 14-3-3 pulldowns performed as described in the methods. Pulldowns were blotted for the presence of Brf1 while lysates were blotted
for phospho p38, total p38 and GAPDH. DRB 5,6-dichloro-1b-1-ribofuranosylbenzimidazole.
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MK2 and MK3 regulate IL-33-induced neutrophil
recruitment in vivo
Intraperitoneal injection of IL-33 in mice has previously
been shown to promote neutrophil recruitment in wild-
type but not Wsh/sh mice, which lack mature mast cells.54
We therefore tested the effect of IL-33 injection in MK2/3
double knockout mice (Figure 7a). Control experiments
using LPS demonstrated that MK2/3 knockout mice
recruited more neutrophils compared to wild-type animals,
arguing against an essential role for MK2/3 in neutrophil
recruitment. In contrast, IL-33 injection recruited much
fewer neutrophils in MK2/3 knockout mice relative to
wild-type controls (Figure 7a). Knockout of MSK1 and 2
did not affect IL-33-induced neutrophil recruitment in this
model (Figure 7a) consistent with the minor effects of
MSKs on IL-33-induced cytokine production in isolated
mast cells (Supplementary figure 2). To confirm that loss
of MK2/3 in mast cells was able to affect the ability of these
cells to secrete chemoattractant for neutrophils, peritoneal
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Figure 6. Inhibitors of the PI3 kinase–Akt pathway reduce IL-33-induced cytokine induction. (a) Wild-type BMMCs were pretreated where
indicated with 1 lM PI-103, 1 lM GDC-094, 1 lM Akti 1/2 or 1 lM MK2206. Cells were then stimulated with 10 ng mL1 IL-33 for 8 h or left
unstimulated and the levels of TNF, IL-6, IL-13 and GM-CSF secreted into the media determined. (b) As (a) except cells were stimulated for 1 h
with 10 ng mL1 IL-33. Total RNA was then extracted and the induction of TNF, IL-6, IL-13 and GM-CSF mRNA determined relative to
unstimulated cells. In (a) and (b), a P < 0.5 is indicated by * and P < 0001 by *** (Holm–Sidak test following one-way ANOVA). (c) Wild-type
BMMCs were pretreated where indicated with 1 lM PI-103, 1 lM GDC-094 or 5 lM PF-3604422. Cells were then stimulated with 10 ng mL1 IL-
33 for 8 h or left unstimulated and the levels of TNF, IL-6, IL-13 and GM-CSF secreted into the media determined. In (a–c), graphs show the
mean and standard deviation of independent cultures from four mice. A P-value (two-tailed Student’s t-test) between the IL-33-stimulated cells
and other conditions of <0.05 is indicated *, <0.01 by ** and <0.001 by ***. (d) Wild-type MK2/3 KO BMMCs were stimulated with
10 ng mL1 IL-33 for the indicated times. Cells were then lysed and the levels phospho-Ser473 Akt, phospho-Thr308 Akt, total Akt and GAPDH
were determined by immunoblotting. (e) Wild-type BMMCs were incubated where indicated with 1 lM VX-745. Cells were stimulated with
10 ng mL1 IL-33 for the times shown and blotted for the indicated proteins.
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mast cells were cultured from wild-type and MK2/3
knockout mice. These cells were then used in Transwell
assays to examine their ability to promote the migration of
wild-type neutrophils. The presence of mast cells in the
lower chamber was able to stimulate a low level of
neutrophil migration. Stimulation of the wild-type mast
cells with IL-33 resulted in an increased neutrophil
migration. IL-33 stimulation of MK2/3 knockout cells
resulted in an increase in neutrophil migration, but this
was lower than seen with wild-type mast cells (Figure 7b).
IL-33 stimulated the production of the chemokines CCL3
and CCL4 by peritoneal mast cells, and this was reduced by
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Figure 7. MK2/3 are required for neutrophil recruitment following intraperitoneal injection of IL-33. (a) Wild type, MK2/3 or MSK1/2 were
injected with either PBS, 5 lg kg1 IL-33 or 2 mg kg1 LPS. After 3 h, mice were sacrificed and the peritoneum washed to obtain cells. The %
of neutrophils (CD11b+/Gr1+) in the peritoneal wash was determined by staining for CD11b and Gr1 and analyzed by flow cytometry. Graphs
show average and standard deviation with crosses representing data for an individual mouse. Two-way ANOVA testing between wild-type and
MK2/3 knockout mice indicated a significant interaction between genotype and treatment (F = 19.34, P < 0.001). For post hoc analysis on the
effect of genotype within treatment groups, a P < 0.01 is indicated ** and I < 0.001 by ***. The difference between MSK1/2 knockout and
wild-type animals treated with IL-33 was not significant (P < 0.05, Student’s t-test). (b) Transwell assays were used to determine the migration of
wild-type neutrophils in response to wild-type or MK2/3 knockout peritoneal mast cells (4 biological replicates per genotype) that were either
unstimulated or treated with IL-33, as described in the methods. Blank indicated wells with neutrophils but no mast cells. Two-way ANOVA
testing between wild-type and MK2/3 knockout mast cells indicated a significant interaction between genotype and treatment (F = 12.404,
P < 0.004). For post hoc analysis on the effect of genotype within treatment groups, a P < 0.01 is indicated by ** and P < 0.001 by ***. (c)
Peritoneal mast cells were stimulated with 10 ng mL1 IL-33 for the indicated times and the levels of CCL3, CCL4 and CXCL2 in the media
determined. Data show mean and standard deviation of four biological replicates per genotype. Two-way ANOVA testing between wild-type and
MK2/3 knockout mast cells indicated a significant effect of genotype (F = 160.7, P < 0.001 for CCL3; F = 5.26, P = 0.034 for CCL2
and F = 151.7, P < 0.001 for CXCL2). For post hoc analysis on the effect of genotype at specific times, a P < 0.05 in indicated by *, <0.01 by **
and <0.001 by ***.
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knockout of MK2 and 3 (Figure 7c). CCL3 has previously
been reported to be a relatively poor chemoattractant for
neutrophils, but its ability to promote neutrophil
recruitment is increased when the neutrophils are
stimulated with GM-CSF.55 In line with this, we observed a
greater attraction of neutrophils to a combination of CCL3
and GM-CSF than CCL3 alone in Transwell assays
(Supplementary figure 10). CXCL2 was also detected in the
media from peritoneal mast cells. While the levels were not
increased by IL-33 treatment, lower levels were
detected from MK2/3 knockout than wild-type mast cells
(Figure 7c).
DISCUSSION
p38a has an established role in regulating cytokine
production downstream of TLR signaling in macrophages
and dendritic cells. With the exception of TLR3, TLRs
can stimulate p38 activity via Myd88, a pathway shared
with IL-1 receptor family members including the ST2/IL-
1RAcP IL-33 receptor. We show here that treatment of
BMMCs with the p38a/b inhibitor VX-745 greatly
inhibited the IL-33 induced production of TNF, IL-6, IL-
13, GM-CSF, CCL3 and CCL4. This is in agreement with
previous studies have also shown that p38 inhibitors can
block IL-33-induced TNF, IL-6 and IL-13 production in
BMMCs.38,39 p38a regulates cell function in part via the
activation of two groups of downstream kinases, MK2/3
and MSK1/2, both of which impact on TLR-induced
cytokine production in macrophages.18 Both MK2/3 and
MSK1/2 were activated in response to IL-33 in BMMCs.
In the case of MSK1/2, inhibition of both the p38a and
ERK1/2 MAPK pathways was required to block IL-33-
induced MSK1 activation and phosphorylation of the
MSK substrate CREB, a finding consistent with MSK
activation in response to TLR-stimulated macrophages.25
MSK1/2 knockout did not have a major effect on
cytokine production in IL-33-stimulated BMMCs. While
MSKs are known to regulate Myd88-dependent cytokine
induction in macrophages and dendritic cells, they are
not required for TLR-induced IL-10 production in B
cells.25,56,57 The role of MSKs in cytokine induction
therefore seems to be cell type specific.
In contrast to MSK1/2, MK2/3 knockout had a much
greater impact on cytokine production in IL-33-
stimulated BMMCs. MK2/3 knockout greatly reduced
TNF, IL-6, IL-13, GM-CSF, CCL3 and CCL4 secretion in
response to IL-33 in BMMCs, a finding consistent with a
recent report showing MK2/3 knockout reduced IL-33
stimulated IL-6 and IL-13 production in BMMCs.40
MK2/3 knockout reduces p38a levels because of a
noncatalytic role for MK2 in stabilizing p38a. The results
from the MK2/3 knockout cells could be interpreted as
either being due to a loss of p38a or a direct role for
MK2/3 catalytic activity in regulating cytokine induction.
We therefore examined the effects of three MK2/3
inhibitors—these did not affect p38a expression levels
but did replicate the effects of MK2/3 knockout on
cytokine production.
In both macrophages and dendritic cells, MK2 is
required for maximal TNF production;28 however, in
these cell types, MK2 and 3 are not essential for the
production of all cytokines. For example, MK2 knockout
reduced IL-6 production in macrophages on prolonged
LPS stimulation but initial IL-6 production was not
reduced,58 while in dendritic cells MK2 knockout did
not reduce IL-6 or IL-12 production.59 In agreement
with these reports, we found that MK2/3 knockout did
not prevent LPS-induced IL-6, IL-13 or IL-12p40
production in BMDMs or GM-CSF differentiated bone
marrow cells. The reason for the more extensive role of
MK2 and MK3 in mast cells is not clear; however, our
data would suggest that MK2 and MK3 regulate
cytokines in mast cells via different mechanisms than
they use in macrophages.
The regulation of cytokine production by MK2 and
MK3 in mast cells is likely to involve regulation of both
transcription and mRNA stability, and relative
contribution may be cytokine specific. For both IL-6 and
IL-13, MK2/3 knockout reduced the induction of the
primary transcript, suggesting a role for MK2/3 in the
transcription of these genes. In contrast, for TNF and
GM-CSF MK2/3 knockout did not have a negative effect
on induction of the primary transcript but did affect the
stability of the mRNA suggesting that MK2/3 regulate
these genes via a post-transcriptional mechanism. The
post-transcriptional regulation of cytokines by MK2/3 in
macrophages has been shown to involve the protein TTP,
which regulates stability and/or translation of AU-rich
element containing mRNAs, including TNF.40 TTP,
however, did not contribute to the regulation of cytokine
production in IL-33-stimulated BMMCs. Neither TTP
knockout nor Ser to Ala knockin mutation of the two
major MK2 phosphorylation sites in TTP affected IL-33
stimulated production of TNF, IL-6, IL-13 or GM-CSF in
BMMCs. MK2/3 did, however, regulate mRNA stability
in IL-33-stimulated BMMCs; TNF and GM-CSF mRNA
stability were reduced in MK2/3 knockout BMMCs.
Brf1 (Zfp36 l1) and Brf2 (Zfp36 l2) are related to TTP,
and similar to TTP, are known to regulate mRNA
stability.26,50,52,53 The role of Brf1 and 2 in immunity,
however, has not been studied as extensively as that of
TTP. Brf1 and Brf2 are involved in early B-cell
development where they regulate senescence to enable
recombination at the immunoglobulin locus60 while in T-
cell development they are involved in the b-selection
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checkpoint, and loss of Brf1 and -2 results in leukemia.61
The roles of Brf1 and -2 in innate immune cells are not
well understood. Brf1 can be induced by inflammatory
stimuli in macrophages; however, Brf1 knockout, unlike
TTP knockout, does not affect TNF or IL-6 induction in
these cells.62 Immunoblotting showed that BMMCs
expressed Brf1 and that MK2/3 knockout or inhibition
reduced Brf1 phosphorylation on Ser92. Two additional
sites exist in Brf1 that conform to the MK2 consensus
sequence, and it is possible that these sites are also
phosphorylated by MK2/3 in IL-33-stimulated mast cells.
The lack of phospho-specific antibodies to these sites
means we were not able to address this directly. The
MK2 consensus sequence (/-X-R-X-X-pS/T) is similar to
that required for binding to 14-3-3 proteins. Following
IL-33 stimulation, Brf1 was able to bind to 14-3-3
proteins and this was blocked by MK2/3 inhibitors or
MK2/3 knockout. It is therefore possible that MK2/3
regulate cytokine stability downstream of IL-33 via Brf1
phosphorylation resulting in Brf1 being sequestered by
14-3-3 proteins.
In addition to regulating TTP in TLR-stimulated
macrophages, MK2/3 also contribute to the activation of
the PI3 kinase–Akt pathway. While the molecular
mechanism behind this is unclear, in macrophages MK2/
3 were found to act at the level of PIP3 production in
the membrane, either via promoting PI3 kinase activity
or inhibition of PIP3 phosphatases.48 We found that in
BMMCs, IL-33 was able to promote activation of Akt as
judged by phosphorylation of Akt on Ser473 and Thr308.
Drube et al. have also recently reported that IL-33 can
induce Ser473 phosphorylation in Akt, although Thr308,
which is essential for Akt activation, was not addressed in
this study.40 Drube et al. also reported that MK2/3
knockout abolished IL-33-induced Akt Ser473
phosphorylation and suggested that this contributed to
the ability of MK2 and MK3 to regulate IL-6 and IL-13
production. In contrast, we did not see complete
inhibition of Ser473 or Thr308 phosphorylation by MK2/
3 knockout or p38 inhibition, although MK2/3 were
more important in regulating the kinetics of Akt
phosphorylation in response to IL-33, with the initial
phosphorylation of Akt being slower in the MK2/3
knockouts. The reason for this difference is not clear.
Interestingly, the remaining cytokine induction in the
presence of PI3 kinase or Akt inhibitors was still sensitive
to MK2 inhibitors, indicating that in our experiments
MK2/3 could regulate cytokine induction via a PI3
kinase–Akt independent mechanism.
MK2/3 knockout reduced neutrophil recruitment to the
peritoneal cavity following intraperitoneal injection of IL-
33. Previous studies using this model have found that
neutrophil recruitment did not occur in Wsh/Wsh mice,
which lack mast cells. This could be rescued by injection
into the peritoneal cavity of wild-type BMMCs but not
BMMCs deficient in the IL-33 receptor.63 In vivo,
neutrophil recruitment is tightly regulated and may involve
waves of different factors, including CXCL1/2, CCL3/4 and
leukotriene B4 (LTB4).64,65 The major chemoattractant for
neutrophils in the intraperitoneal IL-33 model is not
known. In response to intraperitoneal injection of LPS,
neutrophil recruitment can be reduced by antibodies
blocking CXCL1 or CXCL2; however, a combination of
both antibodies did not completely block neutrophil
recruitment consistent with the involvement of other
factors.63 Neutralizing antibodies against CXCL1 alone had
no effect on neutrophil recruitment following
intraperitoneal injection of IL-33.54 LPS could activate
both macrophages and mast cells in the peritoneal cavity,
and thus both cells types could contribute to neutrophil
recruitment in this model. Of note, MK2/3 knockout did
not decrease neutrophil recruitment in response to LPS,
which is consistent with the reduced dependence on MK2
and MK3 for the production of proinflammatory cytokines
in macrophages relative to mast cells. In contrast, mast
cells comprise the major ST2+ cell population in the
peritoneal wash. The low numbers of mast cells present,
however, makes direct measurement of chemokines in the
peritoneal wash following IL-33 injection problematic and
we failed to detect cytokines in the peritoneal wash
following IL-33 injection, most probably due to the
dilution during the washing procedure. In BMMC cultures,
IL-33 strongly induced the mRNA for CCL3 and CCL4.
mRNA for CXCL1 and CXCL2 was also induced, but the
fold induction and relative level of these mRNAs was less
than for CCL3 and CCL4. Isolated peritoneal mast cells
produced CCL3 and CCL4 in response to IL-33, and this
was reduced in MK2/3 knockouts relative to wild-type
mast cells. CXCL2 was also detected in the media, but little
stimulation was seen in response to IL-33. As peritoneal
mast cells did not produce high levels of the classical
neutrophil chemokines CXCL1 and -2, it is possible that
neutrophil recruitment in this model may require the
production of multiple factors. TNF knockout BMMCs
were reported to be less effective than wild-type BMMCs at
rescuing neutrophil recruitment in the Wsh/Wsh mice.54
GM-CSF, another MK2/3-dependent cytokine produced by
mast cells, may also play a role in priming neutrophils;
while CCL3 is a poor chemoattractant for na€ıve
neutrophils in vitro, GM-CSF is reported to prime
neutrophils to make them sensitive to CCL3 as a
chemoattractant.55 Further studies will be required to
address these questions. Our data would also not exclude a
role for MK2/3 in other cell types in vivo. Type II innate
lymphoid cells also express the IL-33 receptor and are
present in the mesenteric membranes.13 It is possible that
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IL-33 also induced chemokines in these cells in vivo and
that this could contribute to the neutrophil recruitment.
Together these studies show that MK2 and MK3 are
critical for regulating cytokine production in IL-33- or
LPS-stimulated mast cells. The way in which MK2/3
regulate these processes is cytokine specific and may
occur via transcriptional or post-transcriptional
mechanisms depending on the cytokine. The roles of
MK2 and MK3 in IL-33-stimulated mast cells appear
more extensive than those in TLR-stimulated
macrophages. IL-33 also acts on ILC2s and T-cell subsets,
it will therefore be interesting to determine how MK2
and 3 affect IL-33 responses in these cells.
METHODS
Mice
TTP knockout, TTP S52A/S178A double knockin, MK2/3
double knockout, MSK1/2 double knockout and Myd88
knockout mice have been described previously and had been
backcrossed onto C57Bl/6 for at least 12
generations.27,30,34,44,47,66 Mice were housed in individually
ventilated cages and allowed free access to food and water.
Colonies were maintained under specific pathogen-free
conditions and work was approved via local ethical review and
carried out subject to a UK Home Office license.
Cell culture
BMMCs were derived from adult mice. Mice were sacrificed and
femurs excised under sterile conditions. The bone marrow was
flushed from the femurs with sterile PBS and the bone marrow
suspension was passed through a 100-lm cell strainer (Greiner
bio-one, Stonehouse, UK). Cells were centrifuged at 340 g for
5 min, and the pellet was resuspended in 25 mL mast cell media
[RPMI 1640 medium containing 10% FBS (Biosera/Labtech,
Heathfield, UK), 5 mM L-Glutamine (GIBCO Life Technologies),
100 U mL1 Penicillin (GIBCO Life Technologies), 100 lg mL1
Streptomycin (GIBCO Life Technologies, Fisher Scientific,
Loughborough, UK), 25 mM HEPES (Lonza, Edinburgh, UK),
1 mM sodium pyruvate (Lonza), 1X nonessential amino acids
(Lonza), 50 lM 2-mercaptoethanol and 30 ng mL1 IL-3
(PeproTech. London, UK)] and transferred to a 75-cm2 tissue
culture flask. The cells in suspension were cultured for 5–6 weeks
at 37°C and 5% CO2, and were split twice a week to refresh the
media and maintain their density at approximately
1 9 106 cells mL1. For measurement of cytokine production,
cells were suspended in fresh media and then rested for 48 h
before stimulation with IL-33.
To culture peritoneal mast cells from mice, the peritoneal
cavity was washed with PBS with 2 mM EDTA and 0.5% BSA.
Cells were pelleted by centrifugation and resuspended in RPMI
1640 supplemented with 10% FBS (Biosera/Labtech), 5 mM L-
Glutamine (GIBCO Life Technologies), 100 U mL1 Penicillin
(GIBCO Life Technologies), 100 lg mL1 Streptomycin
(GIBCO Life Technologies), 25 mM HEPES (Lonza), 1 mM
sodium pyruvate (Lonza), 1X nonessential amino acids
(Lonza), 50 lM 2-mercaptoethanol, 20 ng mL1 SCF
(PeproTech) and 30 ng mL1 IL-3 (PeproTech) and incubated
at 37°C and 5% CO2. After 24 h, non-adherent cells were
discarded and the media replaced. Thereafter, both suspension
and adherent cells were passaged into fresh media every 3 days
and the cells used for experiments at 14 days. Analysis of the
cells by flow cytometry showed that at 14 days they were >94%
positive of c-kit and FceR and expressed the ST2 receptor.
BMDMs were cultured as described previously while GM-
CSF bone marrow-differentiated cells were cultured as for
BMDMs except that the M-CSF in the culture media was
replaced with 5 ng mL1 GM-CSF (PeproTech).67
Unless otherwise indicated, kinase inhibitors were dissolved
in DMSO and used at the following final concentrations: VX-
745 (Selleck, Stratech, Ely, UK), 1 lM; PI-103 (Merck
Millipore, Watford, UK), 1 lM; GDC-0941 (Axon Medichem,
Groningen, Netherlands), 1 lM; Akti 1/2 (Merck Millipore),
1 lM; MK2206 (Selleck), 1 lM; PF-364402 (Tocris, Bio-
Techne, Abingdon, UK), 5 lM; Cmp28 (compound 28 in Ref.
68,69, synthesized in house), 5 lM; Cmp2s (Compound 2s in
Ref. 68,69 synthesized in house), 5 lM. Synthesis of Cmp28
and Cmp2s was based on previous publications.68,69 In vitro
kinase screening data for Cmp28 and Cmp2s were carried out
by Merck Millipore and for PF 364402 by the MRC
International Centre for Kinase Profiling (Dundee, http://
www.kinase-screen.mrc.ac.uk). Cells were stimulated as
indicated in the legends using 10 ng mL1 murine IL-33
(PeproTech) or 100 ng mL1 LPS (Escherichia coli strain O26:
B6; Sigma; L2654). For the zero-time stimulations in the
figures, cells did not receive any IL-33 or LPS. The inhibitors
did not compromise the viability of the mast cells at the
concentrations and times used in this study (Supplementary
figure 11). IL-33 and GM-CSF were from PeproTech and
CCL3 was from Biolegend UK (London).
Flow cytometry of mast cells
Cells were pelleted and resuspended in PBS containing 1%
FCS and incubated with FcBlock (1:50, BD Biosciences, San
Jose, US) for 10 min and then stained with anti-c-Kit-FITC (1
in 500, BD Biosciences, #553354), anti-FceR1-PE (1 in 400,
eBiosciences VWR International Ltd Lutterworth, UK, #12-
5898-81) and anti-ST2-BV421 (1 in 400, BioLegend #145309)
for 30 min. Cells were then washed twice and analyzed by
flow cytometry. For analysis, live cells were identified by
gating based on forward and side scatter.
Immunoblotting
Cells were lysed in triton lysis buffer: 50 mM Tris-HCl (pH
7.5), 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate,
50 mM sodium fluoride, 1 mM sodium pyrophosphate, 0.27 M
sucrose, 1% (vol/vol) Triton X-100, 0.1% (vol/vol) 2-
mercaptoethanol, 1 lg mL1 aprotinin, 1 lg mL1 leupeptin,
1 mM PMSF. Lysates were clarified by centrifugation (20 800 g
for 10 min at 4°C) and supernatants snap-frozen and stored at
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80°C. Protein concentration was determined with Coomassie
Protein Assay Reagent (Fisher Scientific, Loughborough, UK).
Proteins were separated on 10% polyacrylamide gels and
immunoblotting carried out using standard techniques.
Antibodies recognizing phospho-Thr180/Tyr182 p38 (#4511),
total p38 (#9212), total ERK1/2 (#9102), phospho-Ser473 Akt
(#9271), phospho-Thr308 Akt (#9275), BRF1/2 (#2119),
phospho-Ser376 MSK1 (#9591), phospho-Ser133 CREB
(#9198), GAPDH (#2118), phospho-Ser376 MSK1 (#9591),
phospho-Ser82 Hsp27 (#2406), phospho-Thr334 MK2 (#3041)
and total MK2 (#3042) were from Cell Signaling Technology
(Hitchin, UK) and used at a dilution of 1 in 1000. Sheep anti-
PKB alpha (S742B) and sheep anti-MSK1 (S804B) were from
the Division of Signal Transduction Therapy (University of
Dundee) and used at a concentration of 1 lg mL1. The
phospho-Ser92 Brf1 antibody was from Abcam (Cambridge,
UK, #AB79191) and used at 1:1000. Typically, two biological
replicates were included in blotting experiments and data
shown are from one replicate. The experiments shown are
representative of multiple experiments.
14-3-3 pulldown
BMMCs were pretreated for 1 h with DMSO or 5 lM Cmp2s
before stimulation with 10 ng mL1 IL-33 (PeproTech). Cells
were lysed in 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM
EDTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride,
1 mM sodium pyrophosphate, 0.27 M sucrose, 1% (vol/vol)
Triton X-100, 0.1% (vol/vol) 2-mercaptoethanol, 1 lg mL1
aprotinin, 1 lg mL1 leupeptin, 1 mM PMSF (triton lysis
buffer). Lysates were clarified by centrifugation (13,000 rpm
for 10 min at 4°C). Protein concentration was determined
with Coomassie Protein Assay Reagent. A quantity of 1 mg of
lysate per condition was precleared using Sepharose beads for
1 h and then incubated for 16 h at 4°C with 14-3-3-Sepharose
beads.70 Beads were pelleted by centrifugation and washed two
times in triton lysis buffer with 0.15 M NaCl and once in
triton lysis buffer. When indicated in the figure legends,
samples were treated with phosphatase to dephosphorylate
the proteins. To phosphatase treat samples, following the
pulldown beads were pelleted by centrifugation and washed
three times in PMP buffer (New England Biolabs, Hitchin,
UK) and treated with or without 1000 units of k phosphatase
(New England Biolabs) in PMP buffer at 30°C for 30 min. 2X
SDS sample buffer was added directly to beads which were
then boiled for 10 min to release bound proteins.
qPCR analysis
Total RNA was extracted from cells following stimulation using
RNeasy kits (Qiagen, Manchester, UK), according to
manufacturer’s instructions. A quantity of 0.5–1 lg RNA was
reverse transcribed into cDNA using iScript and the resulting
cDNA analyzed by qPCR using a Sybr-Green based detection
(Takara Bio Europe, Saint-Germain-en-Laye, France). 18s and/
or GAPDH were used for normalization and results calculated
as fold stimulation relative to the unstimulated wild-type cells as
described.42 Primers used are listed in Supplementary table 2.
Analysis of cytokine levels
Following stimulation of cells, the levels of TNF, IL-6, IL-10,
IL-13, IL-12p40, GM-CSF, CCL3, CCL4 and CXCL2 present in
the media were determined via a multiplex Luminex based
method (Bioplex, BioRad, Watford, UK). For the analysis of
intracellular TNF levels, BMMCs were stimulated for 4 h with
10 ng mL1 IL-33 in the presence of 3 lg mL1 Brefeldin A
and 2 lM Monensin to block cytokine secretion. Cells were
then incubated with Fc Block (1 in 50 dilution, BD
Biosciences) for 10 min, fixed and permeabilized (Fixation/
Permeabilization Kit, BD Biosciences) and stained for TNF
(TNF-PE, clone TN3-19.12, Biolegend, 1 in 200) and analyzed
by flow cytometry.
Peritoneal neutrophil recruitment model
Mice were injected intraperitoneally with 100 lL PBS, or
5 lg kg1 IL-33 (PeproTech) or 2.5 mg kg1 LPS (Escherichia
coli strain O26:B6; Sigma; L2654) in 100 lL PBS. After 3 h,
the mice were sacrificed via an increasing concentration of
CO2, and the peritoneal cavity was washed using 4 mL PBS
containing 1% BSA and 5 mM EDTA. Cells were pelleted by
centrifugation and incubated on ice with Fc Block (1 in 50
dilution, BD Biosciences) for 10 min. Cells were then stained
with anti-Gr1-PerCp-Cy5.5 (1 in 800, BD Biosciences,
#552093) and anti-CD11b-APC (1 in 1600, BD Biosciences
#553312) for 30 min. Cells were then washed twice and
analyzed by flow cytometry. For analysis, live cells were gated
based on a forward and side scatter and neutrophils defined as
CD11b Gr1 double-positive cells. Gating and representative
FACS plots are shown in Supplementary figure 12.
Neutrophil isolation
Mouse bone marrow-derived neutrophils were isolated from
femurs and tibias as previously described.71 Briefly, bone
marrow was flushed from the bones with ice cold PBS and
separated on a gradient prepared by overlaying 3 mL
Histopaque 1119 (Sigma), 3 mL Histopaque 1077 (Sigma-
Aldrich, Gillingham, UK) and 1 mL PBS containing the bone
marrow cells. The gradient was centrifuged for 30 min at
900 g without brakes, and neutrophils were collected from the
interface of Histopaque 1119 and Histopaque 1077.
In vitro chemotaxis assay
BMMCs (1 x 106 cells) in 600 lL mast cell media in a 24-well
plate were stimulated with 10 ng mL1 IL-33 for 4 h or left
unstimulated. ThinCert Transwell inserts with 3 lm pore size
(Greiner bio-one) were allowed to equilibrate in wells for
10 min. Neutrophils (1 x 106) in 200 lL mast cell media were
placed in the upper compartment of each of the transwell
chambers. After incubation for 1 h at 37°C and 5% CO2, cells
were harvested from both upper and lower chambers. GR-1+
CD11b+ were enumerated using flow cytometry by
comparison with Precision Count beads (BioLegend) added to
15
PC McCarthy et al. MK2/3 regulate IL-33-induced mast cell responses
each sample. Neutrophil migration was determined as the
percentage of neutrophils migrating to the lower chamber as a
percentage of total neutrophils.
Statistical analysis
Data are presented as mean values  s.d. unless otherwise
stated. A Student’s t-test (two-tailed, unpaired) was performed
in Excel and ANOVA testing in SigmaPlot. For post hoc
analysis of ANOVA tests, the Holm–Sidak method was used.
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